Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 90, Issue , 2015, Pages 90-96

  Nakamura, Hideaki ^a   Koziolová, Eva ^b   Etrych, Tomáš ^b   Chytil, Petr ^b   Fang, Jun ^a   Ulbrich, Karel ^b   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Acid cleavable linkage; Chemical carcinogenesis; Controlled drug release; Dendrimer derived polymer conjugate; EPR effect; HPMA polymer conjugate; Pirarubicin (THP)

Indexed keywords

COPOLYMER; DENDRIMER; HYDRAZONE DERIVATIVE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PIRARUBICIN; POLYAMIDOAMINE; 2,3,10,11-TETRAHYDROXYTETRAHYDROPROTOBERBERINE; ANTINEOPLASTIC AGENT; BERBERINE DERIVATIVE; DOXORUBICIN; DRUG CARRIER; HYDROXYPROPYL METHACRYLATE; METHACRYLIC ACID DERIVATIVE; PAMAM STARBURST; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BODY DISTRIBUTION; CHEMICAL BINDING; COLORECTAL TUMOR; COLUMN CHROMATOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HELA CELL LINE; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MALE; MOLECULAR SIZE; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; SARCOMA 180; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; EXPERIMENTAL MELANOMA; INSTITUTE FOR CANCER RESEARCH MOUSE; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BERBERINE ALKALOIDS; CELL LINE, TUMOR; DENDRIMERS; DOXORUBICIN; DRUG CARRIERS; HELA CELLS; HUMANS; MALE; MELANOMA, EXPERIMENTAL; METHACRYLATES; MICE; MICE, INBRED ICR; NEOPLASMS; POLYMERS;

EID: 84924533936     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.10.007     Document Type: Article

References (25)

1. S. Tsukagoshi [Pirarubicin (THP-adriamycin)], Gan to kagaku ryoho Cancer Chemother. 15 1988 2819 2827
2. L.W. Seymour, K. Ulbrich, J. Strohalm, J. Kopecek, and R. Duncan The pharmacokinetics of polymer-bound adriamycin Biochem. Pharmacol. 39 1990 1125 1131
3. L.W. Seymour, K. Ulbrich, S.R. Wedge, I.C. Hume, J. Strohalm, and R. Duncan N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice Br. J. Cancer 63 1991 859 866
4. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Jpn. J. Cancer Res. 89 1998 307 314
5. P. Chytil, T. Etrych, C. Konak, M. Sirova, T. Mrkvan, J. Boucek, B. Rihova, and K. Ulbrich New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting J. Control. Release 127 2008 121 130
6. T. Etrych, J. Strohalm, P. Chytil, P. Cernoch, L. Starovoytova, M. Pechar, and K. Ulbrich Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 42 2011 527 539
7. T. Etrych, L. Kovar, J. Strohalm, P. Chytil, B. Rihova, and K. Ulbrich Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy J. Control. Release 154 2011 241 248
8. M. Azori Polymeric prodrugs Crit. Rev. Ther. Drug Carrier Syst. 4 1987 39 65
9. A.T. Silva, M.C. Chung, L.F. Castro, R.V. Guido, and E.I. Ferreira Advances in prodrug design Mini Rev. Med. Chem. 5 2005 893 914
10. A. Malugin, P. Kopeckova, and J. Kopecek Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells J. Control. Release 124 2007 6 10
11. H. Nakamura, L. Liao, Y. Hitaka, K. Tsukigawa, V. Subr, J. Fang, K. Ulbrich, and H. Maeda Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo J. Control. Release 165 2013 191 198
12. H. Hatakeyama, H. Akita, and H. Harashima The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors Biol. Pharm. Bull. 36 2013 892 899
13. E. Fleige, M.A. Quadir, and R. Haag Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications Adv. Drug Deliv. Rev. 64 2012 866 884
14. W.C. Zamboni Concept and clinical evaluation of carrier-mediated anticancer agents Oncologist 13 2008 248 260
15. K. Ulbrich, V. Subr, J. Strohalm, D. Plocova, M. Jelinkova, and B. Rihova Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation J. Control. Release 64 2000 63 79
16. K. Ulbrich, T. Etrych, P. Chytil, M. Jelínková, and B. Říhová Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation J. Drug Target. 12 2004 477 489
17. T. Etrych, M. Jelinkova, B. Rihova, and K. Ulbrich New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Control. Release 73 2001 89 102
18. H. Nakamura, T. Etrych, P. Chytil, M. Ohkubo, J. Fang, K. Ulbrich, and H. Maeda Two mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage J. Control. Release 2013
19. H. Maeda Macromolecular therapeutics in cancer treatment: the EPR effect and beyond J. Control. Release 164 2012 138 144
20. H. Sezaki, and M. Hashida Macromolecule-drug conjugates in targeted cancer chemotherapy Crit. Rev. Ther. Drug Carrier Syst. 1 1984 1 38
21. K. Ulbrich, and V. Subr Polymeric anticancer drugs with pH-controlled activation Adv. Drug Deliv. Rev. 56 2004 1023 1050
22. K. Nagai, K. Nagasawa, A. Ishimoto, and S. Fujimoto Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells Cancer Chemother. Pharmacol. 51 2003 512 518
23. M. Pennycooke, N. Chaudary, I. Shuralyova, Y. Zhang, and I.R. Coe Differential expression of human nucleoside transporters in normal and tumor tissue Biochem. Biophys. Res. Commun. 280 2001 951 959
24. C.L. Lo, M.H. Chou, P.L. Lu, I.W. Lo, Y.T. Chiang, S.Y. Hung, C.Y. Yang, S.Y. Lin, S.P. Wey, J.M. Lo, and G.H. Hsiue The effect of PEG-5K grafting level and particle size on tumor accumulation and cellular uptake Int. J. Pharm. 456 2013 424 431
25. A. Schadlich, H. Caysa, T. Mueller, F. Tenambergen, C. Rose, A. Gopferich, J. Kuntsche, and K. Mader Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model ACS Nano 5 2011 8710 8720